Published US Pilot Study Highlights Clinical Experience with CERAMENT® G in Trauma
BONESUPPORT™, a leading company in orthobiologics for the managment of bone injuries, today announces the first publication of a US clinical pilot study reporting on surgical technique and outcomes of CERAMENT G in trauma. Published in OTA International, the study offers practical, real‑world insights for clinicians adopting CERAMENT G in trauma care.
The technique used in this pilot study, conducted at HCA Florida Kendall Hospital, included debridement,
Flow-FX™ 2-CAN® delivery of CERAMENT G, with local antibiotic elution, and when required, stable fixation. Patients with either fracture related infections or osteomyelitis, were followed for an average of 14.4 months. Across all cases, the authors reported no recurrence of infection, no major complications or amputations and radiographic union.
“This first US‑based publication from a single Level‑1 trauma center, evaluating CERAMENT G provides a clear, technique‑driven guidance for surgeons managing challenging cases after trauma. Despite its pilot scale, it underscores the effectiveness of CERAMENT G in intramedullary use, combining infection control with reliable bone healing. It further strengthens our momentum in the US trauma market by highlighting a technique well aligned with American surgical practice,” said Torbjörn Sköld, CEO of BONESUPPORT.